17 results about "Life expectancy" patented technology

A system for collecting physiological data from a patient is disclosed. The system includes a reusable module and a disposable module. The disposable module collects and transmits physiological data to the reusable module, which in turn transmits the physiological data to a patient monitoring system. The reusable module accesses operation data from the disposable module to validate the disposable sensor assembly. Optionally, the operation data includes sensor life data that may be used to determine life expectancy of disposable module. The disposable sensor assembly may store the physiological data for a predetermined length of time when there is no wireless communication established for the reusable module.

The invention discloses a prediction method and system for prolonging human life years by health intervention service, and relates to the technical field of data processing, and the method comprises the steps: building a health prediction model, and according to all-cause mortality and disease morbidity data of different genders and age groups, calculating a health prediction model; predicting the death probability of the crowd of each age group, the number of years of survivors of each age group, the total number of years of survivors and the expected life; in combination with the prevalence condition of general population health risk factors and the relative risk degree of all-cause death, calculating the life number of individuals who carry out health intervention earnings on different risk factors, and calculating the overall health score of the current individual; evaluating the health condition of the current individual according to the total health score of the current individual, discovering key risk factors, and making an intervention scheme. The life expectancy of healthy or chronic disease patients can be measured and calculated, and the method is suitable for application scenes of health intervention service evaluation.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to cancer. In particular, the disclosure includes the identities of genes that are expressed in correlation with tumor grade. The levels of gene expression are disclosed as a molecular index for determining tumor grade in a patient and predicting clinical outcome, and so prognosis, for the patient. The molecular grading of cancer may optionally be used in combination with a second molecular index for diagnosing cancer and its prognosis. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer. For diagnosis or prognosis, the disclosure further includes methods for determining or selecting the treatment of cancer based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

Method for controlling a device (100) and / or an adherence machine, wherein the method comprises: acquiring (S10) biomarker data, wherein the biomarker data describe at least one measurable parameter of an individual's biomarker; acquiring (S20) estimation data, wherein the estimation data describe at least one average life expectancy for the individual; determining (S30) individual data based on the acquired estimation data and the acquired biomarker data, wherein the individual data describe at least one individual life expectancy of the individual; determining (S40) control data based on the individual data, wherein the control data represent at least one control command for a device (100) to be controlled, for changing the at least one measurable parameter of the biomarker and / or for changing an individual's behavior;Control (S50) of the device (100) based on the determined control data, wherein at least one adjustable parameter of the device (100) is changed; and / or wherein at least one optical, haptic and / or acoustic interface of the device (100) is activated and / or deactivated based on the determined control data; and / or control of an adherence machine based on the determined control data. The invention also relates to a system or computer program (product).

Provided herein are methods for assessing ageing process, lifespan, life expectancy, biological age and the rate of aging by determining pangenome gene alterations. Also provided are methods for increasing lifespan and / or inhibiting aging.

A system method for selecting an intervention based on effective age, the system including at least a server, the at least a server designed and configured to obtain user data, project an actuarial life expectancy using a user chronological age, determine a telomeric age factor of the user by calculating a variance between the actuarial life expectancy and a projected actual mortality date, calculate an effective age of the user based on the telomeric age factor, and select an intervention from a plurality of configured to reduce the effective age.

The invention relates to an inhibitor of Rho GTPase Cdc42 for use in the prevention and / or treatment of Parkinson's disease of the human or animal body. In a mouse model in which the mice were genetically modified to accumulate α-synuclein and develop Parkinson's disease, it has been shown that the administration of a Cdc42 inhibitor in the diseased mice reduces the accumulation of α-synuclein, improves the symptoms of Parkinson's disease, increases the average life expectancy, and prolongs the total life span. Only minimal to no side effects occurred in the diseased mice.

LIFE ESTIMATION SYSTEM SOLUTION: A lifetime estimation system according to one aspect of the present invention includes a temperature measurement unit configured to measure a temperature of a test object, a temperature control unit, a heating and cooling unit configured to heat and cool the test object, an application unit configured to apply a load other than the temperature to the test object, and a detection unit configured to detect a failure of the test object.SELECTED DRAWING: Figure 1

Provided herein are methods for assessing ageing process, lifespan, life expectancy, biological age and the rate of aging by determining pangenome gene alterations. Specifically, the methods comprising determination of the alteration of the gene composition in mammals and / or non-living genetic elements (NLGE) associated with mammals and at least one of the following: microbiota and / or NLGE associated with microbiota. The methods can be used for increasing lifespan and / or for inhibiting aging in mammals.

One problem to be solved by the present invention is to provide a composition for maintaining or improving life expectancy. The problem is solved by a composition for maintaining or improving life expectancy, which contains α-amino-n-butyric acid or a salt thereof that is pharmaceutically acceptable or is acceptable for a food.

The invention relates to the field of population life prediction, in particular to a population life expectancy estimation method and device, computer equipment and a storage medium, population age distribution raster data prediction is performed based on population association raster data and a pre-constructed nonlinear regression mapping model, and matching is performed in combination with a model life table. The population life expectancy raster data is obtained, the necessary requirement for the number of dead people in a traditional method is overcome, the spatial distribution characteristics of the population life expectancy are represented, and the accuracy of population life expectancy estimation of the target area is improved.

A molecular biology method, by which relative (normalized to an internal control) N6-methyladenine (6 mA) level at a selected site of the mitochondrial (mt) DNA (deoxyribonucleic acid) (mtDNA) in a tissue sample is accurately determined, and this level is projected to a reference “relative mtDNA 6 mA level-age” curve constructed earlier is described. On the reference curve, relative mtDNA 6 mA levels reversely correlate with age; the higher the relative mtDNA 6 mA level, the younger the individual analyzed. Where the value of the relative mtDNA 6 mA level cuts the reference curve, this intersection assigns the corresponding age on the X axis. The reference curve was previously established by determining 6 mA levels at a specific mtDNA site in a large (>1000) number of healthy individuals with known age. The accuracy of the measurement depends on the accuracy of the method by which mtDNA 6 mA level is determined. The method is also suitable for predicting expected lifespan in an individual with known age. The invention relies on our recent biological finding that 6 mA levels at specific mtDNA regions negatively correlate with (is reversely proportional to) the age of the individual analyzed.

The application discloses a kind of expected life estimation method and system for hybrid energy storage system, and hybrid energy storage system is composed of water series hydrogen ion battery and lithium iron phosphate battery.Method includes: defining single cell basic parameters and operating boundary conditions, based on two battery aging paths to build battery aging submodel;Through hybrid operating condition acceleration test, operating data is collected, difference temperature correction coefficient is calculated, and interactive influence factor library is quantified;Using BiLSTM neural network to complete full life cycle data and optimize submodel;Integrate multi-dimensional correction factor to calculate single cell corrected life, determine system expected life by combining preset judging rule, and realize model iterative optimization by comparing actual operating data.System includes parameter definition and model construction, data acquisition and processing, data completion and model optimization, life estimation and iterative optimization module.The application improves the accuracy and adaptability of expected life estimation, and supports the large-scale application of hybrid energy storage system.

A system for collecting physiological data from a patient is disclosed. The system includes a reusable module and a disposable module. The disposable module collects and transmits physiological data to the reusable module, which in turn transmits the physiological data to a patient monitoring system. The reusable module accesses operation data from the disposable module to validate the disposable sensor assembly. Optionally, the operation data includes sensor life data that may be used to determine life expectancy of disposable module. The disposable sensor assembly may store the physiological data for a predetermined length of time when there is no wireless communication established for the reusable module.